An update to "The cost-effectiveness of rotavirus vaccination: comparative analyses for five European countries and transferability in Europe".
A cost-effectiveness analysis of rotavirus vaccination in Belgium, England and Wales, Finland, France and the Netherlands published in 2009 was updated based on recent studies on rotavirus burden of disease and vaccine efficacy. All the qualitative conclusions in the previous study were found to remain valid. Vaccination remains cost-effective in Finland only when using plausible tender prices.
Jit
Mark
M
Mangen
Marie-Josée J
MJ
Melliez
Hugues
H
Yazdanpanah
Yazdan
Y
Bilcke
Joke
J
Salo
Heini
H
Edmunds
W John
WJ
Beutels
Philippe
P
D017281:Cost of Illness; D003362:Cost-Benefit Analysis; D005060:Europe / Q000453:epidemiology; D005759:Gastroenteritis / Q000191:economics / Q000453:epidemiology / Q000517:prevention & control / Q000821:virology; D006801:Humans; D018803:Models, Economic; D012400:Rotavirus Infections / Q000191:economics / Q000453:epidemiology / Q000517:prevention & control*; D022243:Rotavirus Vaccines / Q000191:economics*; D014611:Vaccination / Q000191:economics*
D022243:Rotavirus Vaccines